ESC Premium Access

Interactive discussion: what are the implications of SGLT2 inhibition in HF patients with diabetes?

Topic: Diabetes management
Organised by Academic Medical Center Amsterdam. Dept Vascular Medicine and Physicians' Academy for Cardiovascular Education / Course Director: Prof John Kastelein / Supported by an unrestricted educational grant from Boehringer Ingelheim/Lilly

Congress Presentation

About the speakers

Doctor David Fitchett

St. Michael's Hospital, Toronto (Canada)
18 presentations
0 follower

Professor John J V McMurray

Western Infirmary, Glasgow (United Kingdom of Great Britain & Northern Ireland)
121 presentations

2 more presentations in this session

Introduction - SGLT2 inhibition in diabetes and heart failure: discuss the evidence.

Speaker: Doctor D. Fitchett (Toronto, CA)


SGLT2 inhibition: exploring the evidence in diabetes and heart failure.

Speaker: Professor J. McMurray (Glasgow, GB)


Access the full session

SGLT2 inhibition in diabetes and heart failure: discuss the evidence

Speakers: Doctor D. Fitchett, Professor J. McMurray, Doctor D. Fitchett, Professor J. McMurray

About the event


ESC Congress 2016

27 August - 31 August 2016

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb